Lunit-AstraZeneca Present Joint Research on 'AI-Based Lung Cancer Mutation Prediction' at American Association for Cancer Research

Utilizing Over 12,000 Non-Small Cell Lung Cancer Data Cases

Medical artificial intelligence (AI) company Lunit announced on the 27th that it will present the results of its joint research with AstraZeneca at the '2025 American Association for Cancer Research (AACR 2025)' to be held in Chicago, USA, from the 25th to the 30th of next month.

The two companies have been conducting research using AI to predict EGFR (epidermal growth factor receptor) mutations in non-small cell lung cancer (NSCLC). The presence of EGFR mutations is a key factor in determining a patient's treatment method, but there have been limitations due to long testing times and a lack of medical resources, resulting in insufficient testing.

Accordingly, the two companies applied Lunit's AI pathology analysis solution, 'Lunit SCOPE Genotype Predictor,' to data from more than 12,000 NSCLC patients collected from multinational medical institutions in the United States, China, and Korea, developing a mutation prediction solution with improved performance compared to the AI models previously used for EGFR mutation testing.

As a result of the study, the mutation detection accuracy of Lunit's AI solution achieved an AUC of 0.880, an AI performance evaluation metric, significantly improved from 0.723 of the existing AI model. Additionally, Lunit's AI solution maintained consistent performance in studies that diversified conditions such as various tissue sample types, commercially available pathology scanners by type, and scanning magnifications, demonstrating its potential for use in actual clinical environments.

Seobum Seok, CEO of Lunit, said, "This study is the first collaborative achievement announced since the two companies agreed at the end of last year to jointly develop an AI pathology solution that quickly and efficiently predicts EGFR mutations in non-small cell lung cancer. Based on the research results, we will accelerate the commercialization of the EGFR mutation detection AI solution and expand the scope of collaboration to predict mutations in other cancer types."

Meanwhile, in November last year, Lunit signed a strategic collaboration agreement with global pharmaceutical company AstraZeneca to develop an AI-based digital pathology solution for non-small cell lung cancer, supporting the rapid and accurate detection of EGFR mutations to enable more patients to have treatment opportunities.